Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-κB

Molecular Medicine Reports

Volumn 4, Issue 2, 2011, Pages 221-227

  Liu, An ^a   Chen, Hui ^a   Tong, Hongfei ^a   Ye, Sheng ^a   Qiu, Maixuan ^a   Wang, Zhaohong ^a   Tan, Wei ^a   Liu, Jinxiang ^a   Lin, Shengzhang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Emodin; Gemcitabine; Nuclear factor B; Pancreatic cancer

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; EMODIN; GEMCITABINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CELL LINE SW1990; CANCER CELL LINE SW1990/GZ; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TEMPERATURE; PANCREAS CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; DEOXYCYTIDINE; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EMODIN; HUMANS; NF-KAPPA B; NITRILES; PANCREATIC NEOPLASMS; SINCALIDE; SULFONES;

ANIMALIA;

EID: 79551714920     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.414     Document Type: Article

References (32)

1. Burris Ha III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
2. Demirezer LO, Kuruüzüm-Uz A, Bergere I, Schiewe HJ and Zeeck A: The structures of antioxidant and cytotoxic agents from natural source:anthraquinones and tannins from roots of Rumex patientia. Phytochemistry 58: 1213-1217, 2001. (Pubitemid 34019490)
3. Basu S, Ghosh A and Hazra B: Evaluation of the antibacterial activity of Ventilago madraspatana Gaertn., Rubia cordifolia Linn. and Lantana camara Linn.: isolation of emodin and physcion as active antibacterial agents. Phytother Res 19: 888-894, 2005.
4. Park MY, Kwon HJ and Sung MK: Evaluation of aloin and aloe-emodin as anti-inflammatory agents in aloe by using murine macrophages. Biosci Biotechnol Biochem 73: 828-832, 2009.
5. Liu YX, Shen NY, Liu C and Lv Y: Immunosuppressive effects of emodin: an in vivo and in vitro study. Transplant Proc 41: 1837-1839, 2009.
6. Li J, Liu P, Mao H, Wanga A and Zhang X: Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep 21: 1605-1610, 2009.
7. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM and Lin YW: Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 79: 655-664, 2010.
8. Chun-Guang W, Jun-Qing Y, Bei-Zhong L, Dan-Ting J, Chong W, Liang Z, Dan Z and Yan W: Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur J Pharmacol 627: 33-41, 2010.
9. Huang XZ, Wang J, Huang C, Chen YY, Shi GY, Hu QS and Yi J: Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 7: 468-475, 2008. (Pubitemid 351847069)
10. Olsen BB, Bjørling-Poulsen M and Guerra B: Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action. Int J Biochem Cell Biol 39: 227-237, 2007. (Pubitemid 44548449)
11. Lu HF, Lai KC, Hsu SC, Lin HJ, Kuo CL, Liao CL, Yang JS, Chung JG: Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells. Neurochem Res 34: 1575-1583, 2009.
12. Kuo TC, Yang JS, Lin MW, Hsu SC, Lin JJ, Lin HJ, Hsia TC, Liao CL, Yang MD, Fan MJ, Wood WG and Chung JG: Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappaB in cell survival. J Pharmacol Exp Ther 330: 736-744, 2009.
13. Adachi S, Kokura S, Okayama T, Ishikawa T, Takagi T, Handa O, Naito Y and Yoshikawa T: Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia 25: 210-219, 2009.
14. Banerjee S, Kaseb AO and Wang Z: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69: 5575-5583, 2009.
15. Chen J, Ouyang ZG, Zhang SH and Zhen YS: Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncol Rep 17: 1445-1451, 2007.
16. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861, 2007. (Pubitemid 46762173)
17. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M and Cheng AL: Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 63: 1709-1716, 2002. (Pubitemid 34458010)
18. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G and Schmid RM: Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int J Cancer 105: 735-746, 2003. (Pubitemid 36706095)
19. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999. (Pubitemid 29045184)
20. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G and Schmid RM: Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123: 2052-2063, 2002. (Pubitemid 35408327)
21. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR and Schäfer H: role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251, 2003. (Pubitemid 36712936)
22. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10: 2307-2318, 2004. (Pubitemid 38445688)
23. El-Rayes BF, Shields AF, Vaitkevicius V and Philip PA: Developments in the systemic therapy of pancreatic cancer. Cancer Invest 21: 73-86, 2003. (Pubitemid 36292510)
24. Fernández-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytés A, Real FX, Capella G, Mayo MW, Espinosa L and Bigas A: Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci USA 104: 276-281, 2007. (Pubitemid 46068022)
25. Hernández-Vargas H, Rodríguez-Pinilla SM, Julián-Tendero M, Sánchez-Rovira P, Cuevas C, Antón A, Ríos MJ, Palacios J and Moreno-Bueno G: Gene expression profling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 102: 157-172, 2007. (Pubitemid 46452170)
26. Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P and Grant S: Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 103: 2761-2770, 2004. (Pubitemid 38393035)
27. Jiko M, Yano I, Sato E, Takahashi K, Motohashi H, Masuda S, Okuda M, Ito N, Nakamura E, Segawa T, Kamoto T, Ogawa O and Inui K: Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol 12: 284-290, 2007. (Pubitemid 47262740)
28. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP and Bours V: NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97, 2003. (Pubitemid 36152887)
29. Fenig E, Nordenberg J, Beery E, Sulkes J and Wasserman L: Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. Oncol Rep 11: 213-217, 2004.
30. Kurokawa T, He G and Siddik ZH: Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother Pharmacol 65: 427-436, 2010.
31. Lai GH, Zhang Z and Sirica AE: Celecoxib acts in a cyclooxygenase-2- independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther 2: 265-271, 2003.
32. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J and Sarkar FH: Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65: 9064-9072, 2005. (Pubitemid 41377399)